Accuray reported total net revenue of $104.8 million for the quarter, down 7% from the prior year, with product revenue at $49.7 million (-13%) and service revenue at $55.1 million (-1%). Gross profit fell to $25.3 million, or 24.1% of revenue, and the company posted a net loss of $11.8 million ($0.09 per share). Adjusted EBITDA was $3.8 million versus $6.0 million a year earlier, product orders declined to $48.5 million, and the book-to-bill ratio slipped to 1.0 with an order backlog of $356.2 million.

Since launching its transformation plan in December, Accuray has achieved approximately $10 million in cost and margin improvements through Q3, exceeding interim targets. The company also appointed Paul Miele as Chief Commercial Officer to drive capital device scaling and forged strategic partnerships across imaging, software, workflow and clinical research to enhance its technology ecosystem.

Accuray withdrew its fiscal 2026 financial guidance due to geopolitical uncertainty in the Middle East, which has materially delayed product installations and service revenue in key markets. Management plans to revisit outlook when reporting Q4 results and remains focused on execution in controllable areas.